PACIRA BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
PACIRA BIOSCIENCES, INC. (PCRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $7.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2020-02-21
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was $7.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|
| 2019-12-31 | $7.00M 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |